Takara Bio Inc.
Investor Relations
IR News
IR News
サブ-ナビゲーション
information
News
Corporate Guide
Business
Investor Relations
Management Policy
Financial Data
IR Library
Stock Information
IR Calendar
現在位置:
IR News
FAQ
Contact IR
Disclosure Policy
User Guide
Sustainability
Contact Us
IR News
2025/03/28
[Delayed] Notice Concerning the Absorption-type Merger (Simplified Merger) of the Wholly Owned Subsidiary
（267KB）
2025/02/13
Notice Concerning Revisions to the Financial Results Forecasts
（182KB）
2025/02/13
Consolidated Financial Results for the Nine Months Ended December 31, 2024 (Under Japanese GAAP)
（431KB）
2025/01/27
Notice Concerning Acquisition of Shares of ViSpot, Inc. (to Make It a Subsidiary)
（220KB）
2025/01/15
Notice Concerning Acquisition of Shares of Curio Bioscience, Inc. (to Make It a Subsidiary)
（245KB）
2024/11/08
Notice Concerning Differences between the Financial Forecast and the Actual Results
（209KB）
2024/11/08
Consolidated Financial Results for the Six Months Ended September 30, 2024 (Under Japanese GAAP)
（443KB）
2024/08/08
Consolidated Financial Results for the Three Months Ended June 30, 2024 (Under Japanese GAAP)
（233KB）
2024/07/31
[Delayed] Annual Securities Report for Fiscal Year Ended March 31, 2024
（1,059KB）
2024/06/27
Matters Concerning Controlling Shareholders
（184KB）
2024/05/28
Notice of the 22nd Annual General Meeting of Shareholders
（201KB）
2024/05/10
Notice Concerning Dividends from Surplus
（139KB）
2024/05/10
Consolidated Financial Results for the Fiscal Year Ended March 31, 2024 (Under Japanese GAAP)
（445KB）
2024/02/14
Consolidated finacial results for the nine months ended Dec 31(Under Japanese GAAP)
（368KB）
2023/11/09
Notice Concerning Differences between the Financial Results Forecasts and the Actual Results
（163KB）
2023/11/09
Notice Concerning Revisions to the Financial Results Forecasts
（177KB）
2023/11/09
Consolidated Financial Results for the Six Months Ended September 30, 2023 (Under Japanese GAAP)
（427KB）
2023/08/30
{Delayed] Corporate Governance Report
（1,523KB）
2023/08/08
Consolidated Financial Results for the Three Months Ended June 30, 2023 (Under Japanese GAAP)
（424KB）
2023/08/08
Notice Concerning Revisions to the First Half Financial Results Forecasts
（179KB）
2023/07/31
[Delayed] Annual Securities Report for Fiscal Year Ended March 31, 2023
（1,551KB）
2023/06/29
Matters Concerning Controlling Shareholders
（241KB）
2023/05/11
Notice Concerning Dividends from Surplus
（232KB）
2023/05/11
Takara Bio Group Formulated “Medium-Term Management Plan 2026”
（350KB）
2023/05/11
Consolidated Financial Results for the Fiscal Year Ended March 31, 2023 (Under Japanese GAAP)
（610KB）
2023/03/02
ARTICLES OF INCORPORATION
（111KB）
2023/02/09
Notice Concerning Revisions to the Financial Results Forecasts and Dividend Forecasts （Dividend Increase）
（252KB）
2023/02/09
Consolidated Financial Results for the Nine Months Ended December 31, 2022（Under Japanese GAA）
（456KB）
2023/01/25
[Delayed]Takara Bio Announces Transfer of SAKIGAKE and Orphan Designations for NY-ESO-1/siTCR Gene Therapy Product
（229KB）
2022/11/10
Notice Concerning Revisions to the Financial Results Forecasts and Dividend Forecasts (Dividend Increase)
（186KB）
2022/11/10
Consolidated Financial Results for the Six Months Ended September 30, 2022 (Under Japanese GAAP)
（404KB）
2022/10/25
Notice Concerning Revisions to the First Half Financial Results Forecasts
（244KB）
2022/09/16
[Correction] Annual Securities Report for the Fiscal Year Ended March 31, 2022
（212KB）
2022/09/06
Annual Report 2022
（8,041KB）
2022/08/29
[Delayed] Annual Securities Report for Fiscal Year Ended March 31, 2022
（1,191KB）
2022/08/04
Consolidated Financial Results for the Three Months Ended June 30, 2022 (Under Japanese GAAP)
（394KB）
2022/07/06
[Delayed] Corporate Governance Report
（770KB）
2022/06/13
Notice of the 20th Annual General Meeting of Shareholders
（208KB）
2022/05/12
Notice of Dividends of Surplus
（135KB）
2022/05/12
Consolidated Financial Statements for the Year Ended March 31, 2022 FY2022 (April 1, 2021 - March 31, 2022) [UNAUDITED]
（350KB）
2022/02/10
Notice Concerning Forecast Revisions of Financial Results and Dividend (Dividend Increase)
（250KB）
2022/02/10
Consolidated Financial Statements for the Third Quarter Ended December 31, 2021 FY2022 (April 1, 2021-March 31, 2022) [UNAUDITED]
（771KB）
2022/01/24
Notice Concerning Recording of Extraordinary Gains and Losses Related to Subsidization
（248KB）
2022/01/20
[Delayed] Corporate Governance Report
（768KB）
2021/11/09
Notice of Revisions of Financial Forecast and Dividend Forecast (Dividend Increase)
（138KB）
2021/11/09
Consolidated Financial Statements for the Second Quarter Ended September 30, 2021 FY2022 (April 1, 2021 - March 31, 2022) [UNAUDITED]
（339KB）
2021/10/21
Notice of Revision of Financial Forecast
（241KB）
2021/09/21
Notice of Resolution of the Board of Directors on Selection of “Prime Market” Listing on the Tokyo Stock Exchange under the New Market Segments
（224KB）
2021/08/06
[Updated] Consolidated Financial Statements for the First Quarter Ended June 30, 2021 FY2022 (April 1, 2021 - June 30, 2021) [UNAUDITED]
（596KB）
2021/08/06
[Updated] Consolidated Financial Statements for the First Quarter Ended June 30, 2021 FY2022 (April 1, 2021 - June 30, 2021) [UNAUDITED]
（154KB）
2021/08/03
Notice of Revision of Financial Forecast and Dividend Forecast (Dividend Increase)
（139KB）
2021/08/03
Consolidated Financial Statements for the First Quarter Ended June 30, 2021 FY2022 (April 1, 2021 － June 30, 2021) 〔UNAUDITED〕
（596KB）
2021/05/13
Consolidated Financial Statements for the Year Ended March 31, 2021 FY2021 (April 1, 2020 - March 31, 2021) [UNAUDITED]
（695KB）
2021/02/10
Notice Regarding Forecast Revisions of Financial Results and Dividend (Dividend Increase)
（287KB）
2021/02/10
Consolidated Financial Statements for the Third Quarter Ended December 31, 2020 FY2021 (April 1, 2020 - March 31, 2021)［UNAUDITED］
（915KB）
2021/01/05
Corporate Governance Report
（681KB）
2020/11/25
We have posted "Financial Results Presentation".
（1,020KB）
2020/11/10
Notice Regarding Forecast Revisions of Financial Results and Dividend (Dividend Increase)
（217KB）
2020/11/10
Consolidated Financial Statements for the Second Quarter Ended September 30, 2020 FY2021 (April 1, 2020 - September 30, 2020) [UNAUDITED]
（681KB）
2020/11/06
We have issued "Annual Report 2020".
（1,023KB）
2020/10/21
【Delayed】Announcement on Revision of Financial Forecast
（225KB）
2020/08/05
【Delayed】Announcement on revision of financial forecast
（369KB）
2020/08/05
【Delayed】Consolidated Financial Statements for the First Quarter Ended June 30, 2020 FY2021 (April 1, 2020 - June 30, 2020)
（780KB）
2020/08/04
Summary of Financial Results for the first quarter 2021
（366KB）
2020/08/04
Takara Bio terminates the license agreement relating to Oncolytic Virus C-REV with Tasly Biopharmaceuticals, China
（285KB）
2020/06/26
We have posted "Financial Results Presentation".
（670KB）
2020/06/08
Takara Bio Group’s Formulation of Long-Term Management Plan FY2026 and Medium-Term Management Plan FY2023
（994KB）
2020/05/28
Notice of the 18th Annual General Meeting of Shareholders
（163KB）
2020/05/19
【Delayed】Consolidated Financial Statements for the Year Ended March 31, 2020 FY2020 (April 1, 2019 -March 31, 2020)[UNAUDITED]
（710KB）
2020/05/14
Summary of Financial Results 2020
（430KB）
2020/05/13
【Delayed】Takara Bio has entered into a license agreement relating to C-REV with Tasly Biopharmaceuticals, China
（227KB）
2020/02/13
Consolidated Financial Statements for the Third Quarter Ended December 31, 2019 FY2020 (April 1, 2019 - March 31, 2020)[UNAUDITED]
（625KB）
2019/11/21
We have posted "financial results presentation".
（551KB）
2019/11/12
Consolidated Financial Statements for the Second Quarter Ended September 30, 2019 FY2020 (April 1, 2019 - March 31, 2020)[UNAUDITED]
（626KB）
2019/09/27
Strategic Change in Development of Oncolytic Virus Immunotherapy C-REV
（247KB）
2019/09/27
We have issued "Annual Report 2019".
（1,044KB）
2019/08/14
Corporate Governance Report
（514KB）
2019/08/06
Consolidated Financial Statements for the First Quarter Ended June 30, 2019 FY2020 (April 1, 2019 - March 31, 2020)[UNAUDITED]
（583KB）
2019/05/30
Notice of the 17th Annual General Meeting of Shareholders
（148KB）
2019/05/22
We have posted "Financial Results Presentation".
（820KB）
2019/05/14
Consolidated Financial Statements for the Year Ended March 31, 2019 FY2019 (April 1, 2018 - March 31, 2019)［UNAUDITED］
（795KB）
2019/05/14
Summary of Financial Results 2019
（399KB）
2019/03/29
Marketing Authorization Application for Oncolytic Virus Immunotherapy C-REV for Unresectable or Metastatic Melanoma Submitted in Japan
（194KB）
2019/02/08
Corporate Governance Report
（496KB）
2019/02/06
【Delayed】Consolidated Financial Statements for the Third Quarter Ended December 31, 2018 FY2019 (April 1, 2018 - March 31, 2019)[UNAUDITED]
（932KB）
2019/01/30
Notice Regarding Forecast Revisions of Financial Results and Dividend (Dividend Increase)
（259KB）
2019/01/30
Summary of Financial Results for the third quarter 2019
（488KB）
2018/12/17
Notice Regarding Transfer of Mushroom Business
（316KB）
2018/11/14
We have posted "Financial Results Presentation".
（684KB）
2018/11/06
Consolidated Financial Statements for the Second Quarter Ended September 30, 2018 FY2019 (April 1, 2018 - March 31, 2019)[UNAUDITED]
（728KB）
2018/11/06
Summary of Financial Results for the second quarter 2019
（390KB）
2018/09/28
【Delayed】Notice Regarding Business Reorganization by Simplified Absorption-type Company Split
（241KB）
2018/09/03
We have issued "Annual Report 2018".
（2,549KB）
2018/08/22
Takara Bio entered into a licensing agreement relating to Oncolytic Virus "Canerpaturev" with Dong-A ST, South Korea
（195KB）
2018/07/31
Consolidated Financial Statements for the First Quarter Ended June 30, 2018 FY2019(April 1, 2018-March 31, 2019)[UNAUDITED]
（182KB）
2018/07/31
Summary of Financial Results for the first quarter 2019
（109KB）
2018/06/08
【Delayed】Announcement on revision of Takara Bio Medium-Term Management Plan FY2020
（533KB）
2018/06/08
【Delayed】Consolidated Financial Statements for the Year Ended March 31, 2018 FY2018 (April 1, 2017 - March 31, 2018)[UNAUDITED]
（780KB）
2018/02/13
【Delayed】Consolidated Financial Statements for the Third Quarter Ended December 31, 2017 FY2017 (April 1, 2017 - March 31, 2018) [UNAUDITED]
（832KB）
2018/01/30
Summary of Financial Results for the third quarter 2018
（96KB）
2017/11/28
Consolidated Financial Statements for the Second Quarter Ended September 30, 2017
（1,571KB）
2017/11/06
Revision of Consolidated Business Results Forecast ｆor the First Half of the Fiscal Year Ending March 31, 2018
（221KB）
2017/08/21
Consolidated Financial Statement for the First Quarter Ended June 30, 2017
（891KB）
2017/07/27
Summary of Consolidated Financial Statement for the First Quarter Ended June 30, 2017
（367KB）
2017/05/09
Consolidated Financial Statement for the year ended March 31, 2017, released on May 9, 2017
（791KB）
2017/05/09
Formulation of Takara Bio Medium-Term Management Plan FY2020
（243KB）
Back to List
PAGETOP
PAGETOP
CLOSE
MENU
サイト内検索
menu
JA
EN
contact
gnavi-box
